Upload
naman-maharaja
View
622
Download
9
Embed Size (px)
Citation preview
-
INTRODUCTION
A pharmaceutical and biotechnology company headquartered in Mumbai, India.
- Manufacturing plants in India, UK, Ireland, France and US.
-Subsidiaries in US, UK, Ireland and France.
-Founded by Habil Khorakiwala in the early 1960s.
- First company outside of the US and Europe to manufacture recombinant human insulin.
SWOT ANALYSIS
STRENGTHS
• Strong expertise in the area of Recombinant Biotechnology
• Strong presence in the European market (50%+ revenue comes from Europe)
• Significant ramping up of the US business (with a growth of 50%)
• Robust manufacturing infrastructure• Strong insulin portfolio in India
WEAKNESSES
• Less contribution towards revenues by the US business
• High debt burden
OPPORTUNITIES• Leverage on synergies present in the European
market
• Launch of Glaritus
THREATS
• Integration of European businesses is a major challenge (Negma and Pinewood acquisitions have to be integrated with the UK business)
• Pricing pressure in the US may restrict expected revenue growth (price erosion more than 95%) specially in cephalosporin segment, with growing competition from companies like Orchid Chemicals and Lupin
• High competition for EPO in regulated markets• Increasing competition in the European generic market
with the growing presence of frontline Indian pharma companies including Ranbaxy and Reddys
MARKET
• Annual turnover of US$ 650 million, and a market capitalisation of over $ 1 billion.
• Wockhardt has revenue of Rs 4,501 crore and operating profit (EBIDTA) at Rs 823 crore during the 15 months period (Jan 2009 – Mar 2010).
• For the quarter (Jan-March 2010) , the sales revenue was Rs 872 crore and operating profit (EBITDA) was Rs 158 crore.
GROWTH
• India Business: Wockhardt’s India branded business grew by 24% in Jan-Mar 2010 over the corresponding period of 2009.
• Europe Business: Wockhardt UK grew by 19% compared to the industry growth of only 5% in Jan-Mar 2010 over the corresponding period of 2009.
• USA Business: Wockhardt`s Morton Grove Pharmaceuticals business has shown a robust 40% growth in Jan-Mar 2010 over the corresponding period of 2009.
TOP PRODUCTS
DIABETOLOGY NEPHROLOGY Wosulin (Recombinant Insulin ) Wepox (Recombinant Mopaday (Oral Antidiabetic) Erythropoietin)Glimaday (Oral Antidiabetic)
PAIN MANAGEMENT: NUTRITION Proxyvon Methycobal
DexolacNEURO-PSYCHIATRY
Spasmo-Proxyvon
NEURO-PSYCHIATRY COUGH THERAPY Libotryp Zedex Tryptomer Bro-Zedex
Viscodyne
PRODUCT-WISE VALUES PRODUCTS Value in Crores % +/- %
Spasmo-Proxyvon 89.41 0.21 7.4
Dexolac 61.99 0.14 26.9
Bro-Zedex 30.38 0.07 36.9
Magenta 30.31 0.07 -1.9
Zedex 28.27 0.07 41
Proxyvon 24.2 0.06 21.4
Merideca 23.5 0.05 -17.5
Wokadine 23.47 0.05 36.8
NEW LAUNCHES
• Insulin Glaritus• Tamsulosin capsules(Flomax)• Amoxicillin Clav K OS,• Azithromycin Tablets, • Divalproex Extended Release Tablets• Midazolam HCI Injection, • Nicardipine Injection, • Ranitidine Tablets,• Risperidone Tablets, • Ropinirole HCI Tablets
TOP COMPETITORS
• Aurobindo Pharma Limited• Cipla Limited• Glaxo Smithkline Pharmaceuticals
Limited• Dr. Reddy's Laboratories Limited• Ranbaxy Laboratories Limited